MYC Oncogene in Myeloid Neoplasias

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2012 Aug 23

PMID 22911553

Citations 38

Authors

M Dolores Delgado

Marta Albajar

M Teresa Gomez-Casares

Ana Batlle

Javier Leon

Affiliations

Soon will be listed here.

Abstract

MYC is a transcription factor that regulates many critical genes for cell proliferation, differentiation, and biomass accumulation. MYC is one of the most prevalent oncogenes found to be altered in human cancer, being deregulated in about 50 % of tumors. Although MYC deregulation has been more frequently associated to lymphoma and lymphoblastic leukemia than to myeloid malignancies, a body of evidence has been gathered showing that MYC plays a relevant role in malignancies derived from the myeloid compartment. The myeloid leukemogenic activity of MYC has been demonstrated in different murine models. Not surprisingly, MYC has been found to be amplified or/and deregulated in the three major types of myeloid neoplasms: acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms, including chronic myeloid leukemia. Here, we review the recent literature describing the involvement of MYC in myeloid tumors.

Citing Articles

Specific sDMA modifications on the RGG/RG motif of METTL14 regulate its function in AML.

Zhong Y, Zhang R, Lu L, Tan H, You Y, Mao Y Cell Commun Signal. 2025; 23(1):126.

PMID: 40057764 PMC: 11889898. DOI: 10.1186/s12964-025-02130-1.

Investigation of the impact of bromodomain inhibition on cytoskeleton stability and contraction.

Bigger-Allen A, Gheinani A, Adam R Cell Commun Signal. 2024; 22(1):184.

PMID: 38493137 PMC: 10944605. DOI: 10.1186/s12964-024-01553-6.

Investigation of the impact of bromodomain inhibition on cytoskeleton stability and contraction.

Bigger-Allen A, Gheinani A, Adam R bioRxiv. 2023; .

PMID: 38014184 PMC: 10680757. DOI: 10.1101/2023.11.14.567076.

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling.

Long H, Hou Y, Li J, Song C, Ge Z Int J Mol Sci. 2023; 24(7).

PMID: 37047788 PMC: 10094826. DOI: 10.3390/ijms24076816.

Circulating CD133+/–CD34– Have Increased c- Expression in Myeloproliferative Neoplasms.

Uslu Bicak I, Tokcan B, Yavuz A, Tokdemir S Turk J Haematol. 2022; 40(1):28-36.

PMID: 36458557 PMC: 9979741. DOI: 10.4274/tjh.galenos.2022.2022.0343.

References

Leon J, Ferrandiz N, Acosta J, Delgado M . Inhibition of cell differentiation: a critical mechanism for MYC-mediated carcinogenesis?. Cell Cycle. 2009; 8(8):1148-57. DOI: 10.4161/cc.8.8.8126. View

Hemann M, Bric A, Teruya-Feldstein J, Herbst A, Nilsson J, Cordon-Cardo C . Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005; 436(7052):807-11. PMC: 4599579. DOI: 10.1038/nature03845. View

Dmitrovsky E, Kuehl W, Hollis G, Kirsch I, Bender T, Segal S . Expression of a transfected human c-myc oncogene inhibits differentiation of a mouse erythroleukaemia cell line. Nature. 1986; 322(6081):748-50. DOI: 10.1038/322748a0. View

Iwasaki H, Akashi K . Myeloid lineage commitment from the hematopoietic stem cell. Immunity. 2007; 26(6):726-40. DOI: 10.1016/j.immuni.2007.06.004. View

Uribesalgo I, Buschbeck M, Gutierrez A, Teichmann S, Demajo S, Kuebler B . E-box-independent regulation of transcription and differentiation by MYC. Nat Cell Biol. 2011; 13(12):1443-9. DOI: 10.1038/ncb2355. View

Nesbit C, Tersak J, Prochownik E . MYC oncogenes and human neoplastic disease. Oncogene. 1999; 18(19):3004-16. DOI: 10.1038/sj.onc.1202746. View

Johansson B, Fioretos T, Mitelman F . Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002; 107(2):76-94. DOI: 10.1159/000046636. View

Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-17. PMC: 3187920. DOI: 10.1016/j.cell.2011.08.017. View

Nowicki M, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T . Chronic myelogenous leukemia molecular signature. Oncogene. 2003; 22(25):3952-63. DOI: 10.1038/sj.onc.1206620. View

10.

Calabretta B, Venturelli D, Kaczmarek L, Narni F, Talpaz M, Anderson B . Altered expression of G1-specific genes in human malignant myeloid cells. Proc Natl Acad Sci U S A. 1986; 83(5):1495-8. PMC: 323103. DOI: 10.1073/pnas.83.5.1495. View

11.

Meyer N, Penn L . Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8(12):976-90. DOI: 10.1038/nrc2231. View

12.

Watanabe S, Itoh T, Arai K . JAK2 is essential for activation of c-fos and c-myc promoters and cell proliferation through the human granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells. J Biol Chem. 1996; 271(21):12681-6. DOI: 10.1074/jbc.271.21.12681. View

13.

Varmus H . The molecular genetics of cellular oncogenes. Annu Rev Genet. 1984; 18:553-612. DOI: 10.1146/annurev.ge.18.120184.003005. View

14.

Bazarov A, Adachi S, Li S, Mateyak M, Wei S, Sedivy J . A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res. 2001; 61(3):1178-86. View

15.

Melo J, Barnes D . Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007; 7(6):441-53. DOI: 10.1038/nrc2147. View

16.

Xiang Z, Luo H, Payton J, Cain J, Ley T, Opferman J . Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J Clin Invest. 2010; 120(6):2109-18. PMC: 2877934. DOI: 10.1172/JCI39964. View

17.

Vita M, Henriksson M . The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 2006; 16(4):318-30. DOI: 10.1016/j.semcancer.2006.07.015. View

18.

Larramendy M, Niini T, Elonen E, Nagy B, Ollila J, Vihinen M . Overexpression of translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis. Haematologica. 2002; 87(6):569-77. View

19.

Soucek L, Whitfield J, Martins C, Finch A, Murphy D, Sodir N . Modelling Myc inhibition as a cancer therapy. Nature. 2008; 455(7213):679-83. PMC: 4485609. DOI: 10.1038/nature07260. View

20.

Vasikova A, Belickova M, Budinska E, cermak J . A distinct expression of various gene subsets in CD34+ cells from patients with early and advanced myelodysplastic syndrome. Leuk Res. 2010; 34(12):1566-72. DOI: 10.1016/j.leukres.2010.02.021. View